Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Madmanmadoxon Feb 19, 2018 9:47pm

102 Views

Post# 27585297

RE:RE:RE:RE:RE:RE:100

Might be this one?

https://ard.bmj.com/content/annrheumdis/64/3/449.full.pdf

States that the NO wasn't "statistically different" than Naproxen for WOMAC (pain) or GI (safety), both gave higher odds of ulcers where "10 erosions = 1 ulcer". It will be interesting to read up on how the H2S phase just wrapping up performed relative to this NO one.

Bullboard Posts

Morning Market Outlook for Nov. 14, 2024